vs
Side-by-side financial comparison of Evercore Inc. (EVR) and Hologic (HOLX). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Evercore Inc. runs the higher net margin — 23.0% vs 17.1%, a 5.9% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 2.5%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 1.5%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
EVR vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.0B |
| Net Profit | $322.7M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | — | 22.6% |
| Net Margin | 23.0% | 17.1% |
| Revenue YoY | 100.3% | 2.5% |
| Net Profit YoY | 106.1% | -10.9% |
| EPS (diluted) | $7.20 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $838.0M | $1.0B | ||
| Q1 25 | $699.0M | $1.0B | ||
| Q4 24 | $979.5M | $1.0B | ||
| Q3 24 | $738.4M | $988.0M | ||
| Q2 24 | $693.4M | $1.0B |
| Q1 26 | $322.7M | — | ||
| Q4 25 | $204.0M | $179.1M | ||
| Q3 25 | $144.6M | $187.2M | ||
| Q2 25 | $97.2M | $194.9M | ||
| Q1 25 | $146.2M | $-17.4M | ||
| Q4 24 | $140.4M | $201.0M | ||
| Q3 24 | $78.4M | $178.6M | ||
| Q2 24 | $73.8M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% |
| Q1 26 | — | — | ||
| Q4 25 | 24.2% | 22.6% | ||
| Q3 25 | 20.8% | 22.6% | ||
| Q2 25 | 18.0% | 24.9% | ||
| Q1 25 | 16.0% | -0.7% | ||
| Q4 24 | 21.8% | 22.5% | ||
| Q3 24 | 16.7% | 23.3% | ||
| Q2 24 | 15.9% | 24.1% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 15.7% | 17.1% | ||
| Q3 25 | 13.8% | 17.8% | ||
| Q2 25 | 11.6% | 19.0% | ||
| Q1 25 | 20.9% | -1.7% | ||
| Q4 24 | 14.3% | 19.7% | ||
| Q3 24 | 10.6% | 18.1% | ||
| Q2 24 | 10.6% | 19.2% |
| Q1 26 | $7.20 | — | ||
| Q4 25 | $4.80 | $0.79 | ||
| Q3 25 | $3.41 | $0.84 | ||
| Q2 25 | $2.36 | $0.86 | ||
| Q1 25 | $3.48 | $-0.08 | ||
| Q4 24 | $3.32 | $0.87 | ||
| Q3 24 | $1.86 | $0.75 | ||
| Q2 24 | $1.81 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | — | $5.2B |
| Total Assets | — | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $2.4B | ||
| Q3 25 | $2.4B | $2.2B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $1.8B | $2.3B | ||
| Q2 24 | $1.7B | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $5.2B | ||
| Q3 25 | $1.8B | $5.0B | ||
| Q2 25 | $1.7B | $4.8B | ||
| Q1 25 | $1.5B | $4.6B | ||
| Q4 24 | $1.7B | $4.8B | ||
| Q3 24 | $1.6B | $5.1B | ||
| Q2 24 | $1.5B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $9.2B | ||
| Q3 25 | $4.4B | $9.0B | ||
| Q2 25 | $3.7B | $8.8B | ||
| Q1 25 | $3.3B | $8.5B | ||
| Q4 24 | $4.2B | $8.7B | ||
| Q3 24 | $3.6B | $9.2B | ||
| Q2 24 | $3.3B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $807.5M | $229.9M | ||
| Q3 25 | $560.9M | $355.1M | ||
| Q2 25 | $437.7M | $343.3M | ||
| Q1 25 | $-549.7M | $169.4M | ||
| Q4 24 | $686.4M | $189.3M | ||
| Q3 24 | $234.5M | $367.0M | ||
| Q2 24 | $348.5M | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | $798.6M | $215.2M | ||
| Q3 25 | $541.5M | $341.4M | ||
| Q2 25 | $411.7M | $330.5M | ||
| Q1 25 | $-569.3M | $153.9M | ||
| Q4 24 | $673.1M | $172.5M | ||
| Q3 24 | $226.6M | $350.6M | ||
| Q2 24 | $340.7M | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | 61.6% | 20.5% | ||
| Q3 25 | 51.8% | 32.5% | ||
| Q2 25 | 49.1% | 32.3% | ||
| Q1 25 | -81.4% | 15.3% | ||
| Q4 24 | 68.7% | 16.9% | ||
| Q3 24 | 30.7% | 35.5% | ||
| Q2 24 | 49.1% | 38.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 1.4% | ||
| Q3 25 | 1.9% | 1.3% | ||
| Q2 25 | 3.1% | 1.3% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 1.4% | 1.6% | ||
| Q3 24 | 1.1% | 1.7% | ||
| Q2 24 | 1.1% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.96× | 1.28× | ||
| Q3 25 | 3.88× | 1.90× | ||
| Q2 25 | 4.50× | 1.76× | ||
| Q1 25 | -3.76× | — | ||
| Q4 24 | 4.89× | 0.94× | ||
| Q3 24 | 2.99× | 2.05× | ||
| Q2 24 | 4.72× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
